It is noteworthy to mention that anti-PD-1 therapies are approved for treating solid tumors characterized by microsatellite instability-high (MSI-H), mismatch repair deficiency (dMMR), or high tumor mutation burden (TMB-H), including GBM [90]. Here, PDCD1 is linked to neoplasm.